Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sandoz’ Loryna Strategy Validated; Bayer’s Yaz Patent Struck Down A Year Before Expiration

This article was originally published in The Pink Sheet Daily

Executive Summary

Actavis is relaunching its version of the oral contraceptive after the Federal Circuit reverses a lower court and finds Bayer’s patent is invalid due to obviousness; the appeals court also finds that Biogen Idec’s Rituxan patent does not block GSK’s Arzerra.

You may also be interested in...



Permanent Vaccine Facility Should Be On Standby For Future Pandemics, Moncef Slaoui Says

Operation Warp Speed confirmed the necessity of having a facility on hand to develop and manufacture a vaccine for the next crisis, the outgoing advisor says.

FDA’s COVID-19 Pandemic Plan Calls For Ongoing Clinical Trial Innovation

Broader use of adaptive trial designs and master protocols, checklist-based application review, and enhancement of real-world monitoring of products are among the recommendations of US FDA's COVID-19 Pandemic Recovery and Preparedness Plan (PREPP) report, an effort months in making based on interviews with agency management, staff, and outside stakeholders.

US FDA To Lose Another COVID-19 Response Leader With Anand Shah’s Resignation

Shah, deputy commissioner for medical and scientific affairs, has been overseeing FDA’s COVID-19 Pandemic Recovery and Preparedness Plan. His departure the week of 20 January follows that of FDA Chief Counsel Amy Amin, whose resignation led to dueling appointments to temporarily fill her post.

Topics

Related Companies

UsernamePublicRestriction

Register

OM014079

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel